NEW YORK, NY / ACCESSWIRE / March 30, 2016 / Bronstein, Gewirtz & Grossman, LLC, notifies investors of class action against Skullcandy, Inc. (“Skullcandy” or the “Company”) (NASDAQ: SKUL). The class action has been filed on behalf of a class consisting of all persons or entities who purchased Skullcandy, Inc. securities during the period between August 7, 2015 and January 11, 2016 inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

Skullcandy is a Park City, Utah-based company that markets headphones, earphones, hands free devices, audio backpacks, MP3 players, and other products.

The Complaint alleges that throughout the Class Period, Defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) Skullcandy’s published third quarter and full year 2015 revenue and net income guidance were unattainable; (2) Skullcandy’s published fourth quarter and full year 2015 revenue and net income guidance were unattainable; (3) Skullcandy encountered challenges with its largest China distributor; (4) defendant Rick Alden and Ptarmagin, an entity controlled by Alden, engaged in unusual insider selling and realized proceeds in excess of $4 million with full knowledge of the undisclosed materially adverse facts alleged herein; and (5) as a result, Defendants’ statements about Skullcandy’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

Following this news entering the market, investors suffered damages.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action, visit the firm’s website: http://www.bgandg.com/#!skul/qjb2t. To discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Skullcandy, Inc. you have until April 12, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 438155

NEW YORK, NY / ACCESSWIRE / March 30, 2016 / Attorney Advertising–Bronstein, Gewirtz & Grossman, LLC reminds investors of class action against Imprivata, Inc. (“Imprivata” or the “Company”) (NYSE: IMPR) and certain of its officers. The class action, filed in United States District Court of Massachusetts, is on behalf of a class consisting of all persons or entities who purchased Imprivata securities between July 30, 2015 and November 2, 2015 inclusive (the “Class Period”). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or omitted material information concerning demand for the Company”s IT security offerings and its sales trends, which inflated the price of Imprivata stock. The complaint continues to allege that certain Imprivata executives and insiders took advantage of the inflation by selling more than $72 million worth of personally-held Imprivata stock during this time period.

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint and to join this action, please visit the firm”s site: http://www.bgandg.com/#!impr/x2qgb. To discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Imprivata, you have until April 4, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm”s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 438218

NEW YORK, NY / ACCESSWIRE / March 30, 2016 / Bronstein, Gewirtz & Grossman, LLC, notifies investors of class action against Cardiovascular Systems, Inc. (“Cardiovascular Systems” or the “Company”) (NASDAQ: CSII). The class action has been filed on behalf of a class consisting of all persons or entities who purchased Cardiovascular Systems, Inc. securities during the period between September 12, 2011 and January 21, 2016 inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

Cardiovascular Systems, Inc. is a company devoted to developing and commercializing innovative solutions for treating peripheral and coronary vascular disease.

The Complaint alleges that throughout the Class Period, Defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) Cardiovascular Systems distributed illegal kickbacks to healthcare providers; (2) Cardiovascular Systems engaged in off-label promotion of its medical devices; and (3) Cardiovascular Systems violated FDA laws and regulations in connection with its medical devices. As a result of this, Cardiovascular Systems’ public statements were materially false and misleading at relevant times. Following this information entering the market, investors suffered damages.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action, visit the firm’s website: http://www.bgandg.com/#!csii/pz0v2. To discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Cardiovascular Systems you have until April 12, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 438156

POMPANO BEACH, FL / ACCESSWIRE / March 30, 2016 / Due to technical difficulties from our conference call provider, the conference call passcode was not accepted properly on our update call this morning. The system prompted callers to dial *0 to be connected to the Operator that would then connect you to the call.

For those of you who were unable to connect, a recording of today’s conference call will be made available using one of the following two
methods, where the replay will be available for 10 days.

1) Listen by calling the replay phone number 1-888-286-8010 in the United States and Canada, or 1-617-801-6888 internationally, then referencing the Conference ID 16191135#, available immediately.

2) Listen by visiting www.dshealthgroup.com. This recording will be available starting at 12:00 pm Eastern Daylight Time on Thursday, March 31, 2016.

Note that there was no Q&A session after the call. We have provided the following number for anyone to call to have his or her
individual questions answered personally by the management team: (888) 404-7770 Ext. 3.

About DS Healthcare Group

DS Healthcare Group Inc. (NASDAQ: DSKX) is engaged in the development of biotechnology for topical therapies. It markets through online channels, specialty retailers, distributors, pharmacies, and salons. Its research has led to a highly innovative portfolio of personal care
products and additional innovations in pharmaceutical projects. For more information on DS Health Group’s flagship brand, visit www.dslaboratories.com.

Forward-looking statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe
Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans,
results, or strategies, and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” or “projected.” These
forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the
company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others,
limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed
in reports filed by the company with the Securities and Exchange Commission, which are available at www.sec.gov.

Contact

Investor Relations
DS Healthcare Group, Inc.
(888) 404-7770 Ext. 3
Investors@DSHealthGroup.com

SOURCE: DS Healthcare Group, Inc.

ReleaseID: 438294

BOCA RATON, FL / ACCESSWIRE / March 30, 2016 / Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the year ended December 31, 2015.

Operational Highlights

NovaVision

– NovaVision launched its Internet-delivered therapy suite in June 2015. Novavision’s VRT had hitherto been, in effect, a prototype with a delivery and service model too costly to be broadly affordable and scalable. NovaVision’s development strategy has been to reduce the cost of therapy delivery and make it more efficient and therefore scalable, migrating therapy delivery from provided-hardware to Internet-delivered onto patients’ computers; and to broaden patient benefits by adding its NeuroEyeCoach compensation therapy to complement the VRT restoration therapy in a suite. With this development, NovaVision has been able to reduce the price to patients by 65%, making the therapy truly affordable and scalable. Given the price reduction, the company anticipated an initial decrease in revenues as volumes ramp up due to the new affordable and scalable therapy suite. New U.S. patient starts increased by 139% in the second half of 2015 versus the first half, and by 57% versus the second half of 2014.

– NovaVision has identified a four-part route-to-market strategy aimed at patients and professionals, comprising: direct-to-patient; rehabilitation centers and clinics; stroke associations and support groups; and physicians. Given the company’s limited resources, and the fact that historically over 50% of patients came through the Internet, in August, NovaVision launched a new website, www.novavision.com, as the core of a lead-driven inbound and outbound marketing strategy directed at prospective patients and relatives.

– The European versions of the therapy suite, in English and German, were launched in early December at the 3rd European Congress of NeuroRehabilitation (ECNR) in Vienna, Austria. The new English/German website www.novavision.de was launched in January 2016 and the UK website www.sightscience.com was launched in March 2016.

ViewSite Brain Access System (VBAS)

– 2015 was an important year for significant independent clinical studies. A total of 7 papers were published or presented during 2015, of which 5 were published in peer reviewed journals, making a total of 14 independent clinical papers on VBAS. The 2015 papers expanded the body of clinical evidence supporting the surgical attributes and benefits of VBAS in a number of important ways:

– Expanded the range of types of procedure, such as its usefulness for the military.
– Continued confirmation of broad compatibility with neurosurgical 3rd party technologies, such as the Karl Storz exoscope visualization device.
– The provision of concrete clinical evidence as to how the use of VBAS can reduce not only surgery time but also reduce post-surgery recovery time; both key factors for the reduction of overall hospital cost.
– Expanded the international clinical acceptance of VBAS with studies being published or presented in China, Japan, Mexico and Taiwan.

– Vycor acquired a portfolio of two US pending patents, and had an existing patent allowed, directed to novel neuro-navigation systems for neurosurgical access systems. This important patent purchase and allowance strengthens Vycor’s position in respect of its strategy to develop and commercialize VBAS devices designed to be fully integrated with selected Image Guided Systems (IGS). Vycor continues to build on its patent portfolio, and has filed an additional four new patents for VBAS-related technologies during 2015.

– In March 2016 Vycor launched its VBASMini, two new smaller models of its TC range. The VBASMini was developed in close collaboration with a leading neurosurgeon who had identified a need to develop a much smaller VBAS than those currently available to allow for less invasive surgery yet still enable the use of instruments. The VBASMini is largest clear device available that can fit through a burr hole yet still provide a large enough working channel to be useful in neurosurgery, and was designed to overcome the limitations of carrying out work through the likes of an endoscopic sheath. The smaller size also enables minimally invasive approaches to areas where existing retractors are too potentially invasive, such as the ventricles.

Management Commentary

“We have been encouraged by the progress of NovaVision’s Internet-delivered therapies in the U.S. and the early positive reception in Europe,” said Peter Zachariou, CEO of Vycor Medical. “With the company’s limited resources we are focused initially on direct-to-patient website and social media marketing, before implementing the other marketing strategies. It takes an average of 10 weeks from contact to signing up a patient so the benefits of the new model take time to build.

“Vycor’s flat sales were a reflection of weak US sales in July and August which recovered in September and this recovery has continued into 2016. We have now launched our new VBASMini and have added 17 new sales reps in the US since Q3 2015 so are optimistic for the division.

“We have continued to reduce our operating loss before depreciation and amortization (or “Cash Burn”), which on a non-GAAP basis for the fourth quarter was $256,000 as compared to $459,000 for the fourth quarter of 2014, a reduction of 44%, and are focused on increasing revenues while maintaining our low costs, with the objective of continuing to decrease our Cash Burn.”

2015 Financial Results

Revenue totaled $1.1 million in the twelve months of 2015, as compared to $1.2 million for the prior year. Vycor Medical’s revenue in the twelve months of 2015 decreased by $8,000 to $885,000. This reflected weak sales in particular in the U.S. in July and August, which recovered in September and this recovery continued through December. Gross margin of 88% was achieved for Vycor in 2015 versus 87% in 2014.

NovaVision revenues in the twelve months of 2015 decreased by $104,000. Foreign exchange differences in Europe accounted for $26,000 of the revenue decrease, with the remainder mainly accounted for by the delayed launch of the new Internet-delivered therapy suite. New patient starts in the US for the second six months following the launch increased by 139% over the first six months of 2015 and by 57% over the second six months of 2014. Gross margin for NovaVision was 78% compared to 88% for 2014, which reflected a one-time write-off totalling $21,000 of inventory and components related to the replaced NovaVision legacy hardware delivery model.

Non-GAAP operating expenses in the twelve months of 2015 totaled $2.5 million as compared to $2.6 million in the prior year.

Non-GAAP net operating loss in the twelve months of 2015 was $1.5 million, unchanged from $1.5 million in the prior year.

Non-GAAP net loss in the twelve months of 2015 was $1.5 million, as compared to $1.7 million in the prior year.

Non-GAAP operating loss before depreciation and amortization (or “Cash Burn”) in the twelve months of 2015 was $1.3 million, as compared to $1.4 million in the prior year. This reflected some exceptional costs in the earlier part of the year. For the fourth quarter of 2015 the “Cash Burn” was $256,000 as compared to $459,000 for the fourth quarter of the prior year, a reduction of 44%.

Reconciliation of Non-GAAP Information and Pro Forma Balance Sheet

Non-GAAP Reconciliation

Management uses certain non-GAAP financial measures (including non-GAAP operating expenses and non-GAAP net loss and loss per share), which exclude non-cash amortization of acquired intangible assets, non-cash stock-based compensation, one-time Offering costs and the change in value of derivative warrant liability. Management does not consider these costs in evaluating the continuing operations of the Company. Therefore, management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to analyze further, and more consistently, the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional important information to enable them to assess, in the same way management assesses, the Company’s current and future continuing operations. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP. Set forth below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures.

For the twelve months the Company reported Operating Expenses of $2,965,529 a net operating loss of $1,991,014 and a net loss of $2,083,643.

Vycor’s GAAP operating costs for the twelve months ended December 31, 2015 include non-cash amortization of acquired intangible assets ($234,466) and non-cash stock compensation charges ($274,502). Vycor’s other expenses included a change in derivative liability ($19,792) and a loss on foreign currency exchange ($63,711).

The Company is providing additional non-GAAP financial measures that exclude these charges and expenses, and reconciliation of GAAP to non-GAAP results is provided in the tables included in this release.

Operating Expenses for the twelve months ended December 31, 2015 were $2,456,562, non-GAAP net operating loss was $1,482,046, and non-GAAP net loss was $1,529,756.

About Vycor Medical, Inc.

Vycor Medical (OTCQB: VYCO) is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions. The company has a portfolio of FDA cleared medical solutions that are changing and improving lives every day. The company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach.

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

Vycor Medical, Inc. Contacts:
6401 Congress Avenue
Suite 140
Boca Raton, FL. 33487
(561) 558-2020
info@vycormedical.com

SOURCE: Vycor Medical, Inc.

ReleaseID: 438293

TORONTO, ON / ACCESSWIRE / March 30, 2016 / California Gold Mining Inc. (“California Gold” or the “Company”) (OTCQX: CFGMF) (TSX-V: CGM) announces new assay results from the Company’s recently completed Phase III drill program at its flagship Fremont Project (the “Project”) in Mariposa County, California. The drill campaign concluded on March 5, 2016. A total of 43 diamond holes, and 41,171 feet (12,549 metres) of drilling were completed during the Phase III program.

Vishal Gupta, California Gold’s President and CEO, said, “We continue to be pleased with the results of our first major drill program at the Project. The results continue to meet and exceed our expectations. We have reported assays now from almost half of the Phase III holes. The results to date, including today’s results, are part of the infill component of the drill program that is meant to demonstrate a 43-101 resource estimate expected to be released by the end of May, 2016. In the meantime, we are excited to see the results of our exploration holes, which should start appearing in a few weeks.”

This press release discusses the assay results and corresponding geological interpretation for three holes of the Phase III drill program, namely DD-15-035, 040 and 042. Highlights from these three holes are displayed in the following table. The plan-view collar locations and interpreted geological cross-sections for all three holes can be viewed in Appendices A and B of this press release, respectively. Today’s announcement brings the total number of Phase III drill holes for which assay results have been publicly released to 20. Assay results for the other 17 drill holes were released on November 9, 2015, November 23, 2015, December 15, 2015, January 18, 2016, and February 17, 2016. Further assay results will continue to be released as they become available.

**Notes: Composite grades are length weighted to interval width. Composite true width for DD-15-035 is estimated at 86% of the reported interval. Composite true width for DD-15-040 is estimated at 83% of the reported interval. Composite true width for DD-15-042 is estimated at 91% of the reported interval.

The Phase III drill program commenced on September 11, 2015. It is designed to achieve the following objectives:

-Generation of a maiden resource estimate for the Project covering the main Pine Tree-Josephine mineralized zone;

-Testing the down-dip extension of the shear zone in the main Pine Tree-Josephine mineralized zone to a depth of up to 3,000 feet (roughly 1,000 metres) below surface; and

-Testing the mineralization potential of the five recently discovered mineralized zones on surface, namely Golden Chain, Vermont Slab, Golden Slope, Race Track Meadow and Ogle Canyon originally discussed in the Company’s December 4, 2014 press release.

Discussion of the Phase III Drill Holes

The three holes discussed in this press release are part of the infill drilling segment of the Phase III drill program, focused on providing greater confidence in the geological continuity of the main Pine Tree-Josephine mineralized zone, in order to help generate a maiden resource estimate for the Project.

The results from all currently analyzed Phase III drill holes show strong correlation with the geology documented during the recent Phase I and II diamond, and historic RC, drilling campaigns, and geological analysis of the Pine Tree-Josephine deposit.

A descriptive overview of the geological setting and the various styles of mineralization prevalent at the Project is provided in the Company’s news release dated November 9, 2015.

DD-15-035

Drill hole DD-15-035 was drilled with an azimuth of 244° and an inclination of -62° to a depth of 168.25m (552.0ft).

This hole intersected two important mineralized zones with gold values exceeding 8.0 g/t Au. A 1.1m (3.7ft) interval with an average of 18.58 g/t Au was intersected between 99.7m and 100.8m. This interval is associated with faulting and a quartz vein stockwork near the basal contact of a large fault. Near the base of the tectonic melange a 3.1m (10.0ft) interval with an average of 8.45 g/t Au was intersected between 134.7m and 137.8m. This interval is associated with sulfide replacement mineralization that has been observed in a similar position in previously analysed drill holes. This interval includes an intersection of 1.5m (5.0ft) with an average grade of 15.29 g/t Au (134.7m to 136.2m).

DD-15-040

Drill hole DD-15-040 was drilled with an azimuth of 240° and an inclination of -65° to a depth of 258.8m (849.0ft).

This hole intersected five important mineralized zones with gold values exceeding 1.0 g/t. A 5.5m (18.0ft) interval with an average of 1.01 g/t Au was intersected between 87.2m and 92.7m and is associated with sulphide replacement mineralization in the hanging wall mafic rocks, quartz ankerite veinlets, and minor arsenopyrite mineralization. Within the tectonic melange a 11.5m (37.7ft) interval with an average grade of 1.41 g/t Au was intersected between 155.3m and 166.8m. This interval is associated with massive quartz veins, fault gouge and breccia, and fine-grained, sulphide replacement mineralization that has been observed in a similar position in previously analysed drill holes. This interval includes intersections of 2.3m (7.4ft) with an average grade of 2.01 g/t Au (156.2m to 158.5m); 2.1m (7.0ft) with an average grade of 2.35 g/t Au (160.5m to 162.6m); and 2.0m (6.5ft) with an average grade of 1.87 g/t/ Au (164.8m to 166.8m).

At the footwall boundary of the tectonic melange a 10.5m (34.6ft) interval with an average of 2.31 g/t Au was intersected between 171.8m and 182.3m and is associated with a zone of brecciated quartz veins. This interval includes a 2.4m (8.0ft) intersection with an average grade of 3.89 g/t Au (173.0m to 175.4m). Within the Mariposa Formation sedimentary rocks a 2.6m (8.6ft) interval with an average grade of 4.31 g/t Au was intersected between 195.1m and 197.7m that is associated with an another zone of brecciated quartz veins. This interval includes a 0.9m (3.0ft) intersection with an average grade of 7.95 g/t Au (195.1m to 196.0m). A 1.7m (5.5ft) interval with an average grade of 1.74 g/t Au was intersected between 207.9m and 209.6m, and is associated with a massive quartz vein and minor arsenopyrite mineralization within the Mariposa Formation.

DD-15-042

Drill hole DD-15-042 was drilled with an azimuth of 240° and an inclination of -55° to a depth of 143.1m (469.5ft).

This hole intersected two important mineralized zones with gold values exceeding 1.5 g/t. A 1.5m (5.0ft) interval with an average of 1.70 g/t Au was intersected between 131.4m and 132.9m, and a 1.1m (3.5ft) interval with an average of 1.74 g/t Au was intersected between 142.0m and 143.1m. Both intervals are associated with faulting and cataclasite development in the tectonic melange. It should be noted that the interval between 142.0m and 143.1m was encountered at the end of the drill hole, and as such it is unknown whether elevated gold grades continue to greater depth.

The Company has retained the services of SRK Consulting (Canada) Inc., an internationally recognized, independent resource consulting firm, to advise the Company’s technical team on overall geological interpretation and to act as an independent umpire on assay results.

Description of Quality Assurance & Quality Control (QA/QC) Procedures

The laboratory being used for assay analyses is American Assay Laboratories Inc. (“AAL”) based in Sparks, Nevada (ISO/IEC 17025:2005 Certified).

Prior to transportation of core samples to AAL, all core processing is conducted at the Project site in an enclosed 6,000 sq. ft. office facility. All diamond drill core is logged, photographed and split using core saws. Core from entire holes is being sampled every five feet to compare with the historic RC hole assay intervals. Additionally, sub-samples are being collected within the planned five foot intervals where important geological or mineralization contacts occur to allow better discrimination within the geological model. The minimum sample interval is 1.5 feet.

One half of the split core is transported to AAL by Company employees for prep and analysis. The other half of the core is stored at the Company core storage facility for future inspection and assay verification. All gold analyses of strongly mineralized samples utilize the screened metallics fire (SMF) assay method with a gravimetric finish. At the laboratory, the entire sample is crushed to 90 percent minus ten-mesh. A rotary splitter is used to obtain a 500 gram sample for pulverising. The screened metallics are collected as the plus fraction from a 150-mesh screen at the lab. The plus 150-mesh fraction is fire assayed in its entirety. Two separate one-assay ton fire (1ATF) analyses of the minus 150-mesh fraction are performed and arithmetically averaged. The minus and plus 150-mesh results are then combined for a total screened metallics fire assay.

A full QA/QC program, involving insertion of appropriate blanks and standards is being employed with acceptable results. Generation of QA/QC control charts, and overall independent umpiring of assay results is being conducted by SRK Consulting (Canada) Inc.

Mr. Vishal Gupta, the Company’s President & CEO has reviewed and approved this press release. Mr. Gupta is a P.Geo. registered with the Association of Professional Geoscientists of Ontario (APGO), and a Qualified Person (QP) as defined under National Instrument 43-101. The exploration program at Fremont is being conducted under Mr. Gupta’s supervision.

About California Gold Mining Inc.

California Gold Mining Inc. is focused on developing its flagship Fremont gold project in Mariposa County, California. The project consists of a land package totaling 3,351 acres of historically producing gold mines. The Fremont Property lies within California’s prolific Mother Lode Gold Belt that has produced over 50 million oz of gold historically. The Company purchased the property in March 2013.

CAUTION REGARDING FORWARD-LOOKING INFORMATION

This news release of California Gold contains statements that constitute “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause California Gold’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Forward-looking statements in this document include statements regarding planned exploration work on the Company’s Fremont Property including the anticipated results and timing thereof. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements, and readers are cautioned not to place undue reliance on these forward looking statements. Any factor could cause actual results to differ materially from California Gold’s expectations. California Gold undertakes no obligation to update these forward looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change, unless otherwise required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information contact:

Vishal Gupta
President & CEO
647-977-9267 x333
Website: www.caligold.ca

Appendix A

Orthophoto of the Pine Tree-Josephine Deposit Showing Locations of Completed and Planned Phase III Drill Holes, and Historic Drill Holes

 

Appendix B

 

 

DD-15-035

 

DD-15-040

 

DD-15-042

 

SOURCE: California Gold Mining Inc.

ReleaseID: 438295

TORONTO, ON / ACCESSWIRE / March 30, 2016 / Stakeholder Gold Corp. (TSXV: SRC) (“Stakeholder” or the “Company”) is pleased to announce the appointment of John Nebocat, P.Eng as Vice President of Exploration.

“John brings almost 40 years of exploration experience to the Company, much of which was earned in the Yukon Territory (with Newmont Exploration). Yukon is Stakeholder’s exploration focus area and we are pleased to be able to have John overseeing the Company’s exploration programs. I expect John’s involvement to improve our chances of meaningful and cost effective mineral discovery,” said Chris Berlet, President & CEO of Stakeholder Gold Corp.

In 2016, Stakeholder will be exploring the Ballarat gold project located in the White Gold District of the Yukon Territory. GroundTruth Exploration Inc. will conduct a GT Probe soil exploration program on the Ballarat property’s Northwestern, as well as its Eastern, gold-in-soils anomalies. The Eastern gold-in-soils anomaly is located approximately 500 m from the route proposed for the Kaminak northern route road, where it is expected to cross the eastern section of the Ballarat property.

The work program will begin at the earliest possible time in the 2016 Yukon summer exploration season.

About Stakeholder Gold Corporation

Stakeholder Gold Corp. is a Canadian mineral exploration company headquartered in Toronto, Canada. The primary focus of Stakeholder is to explore and develop the Ballarat Gold Property in the White Gold District of the Yukon Territory.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more Stakeholder Gold Corp. information, please contact

Christopher J. Berlet, CFA
President & CEO
416 525-6869
cberlet@stakeholdergold.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.

Forward-Looking Statements: This news release contains forward-looking statements that include risks and uncertainties. When used in this news release, the words “estimate”, “project”, “anticipate”, “expect”, “intend”, “believe”, “hope”, “may” and similar expressions, as well as “will”, “shall” and other indications of future tense, are intended to identify forward-looking statements. The forward-looking statements are based on current expectations and apply only as of the date on which they were made. The factors that could cause actual results to differ materially from those indicated in such forward-looking statements include changes in the prevailing price of gold, the prevailing price of natural gas, the Canadian-United States exchange rate, amount of gas produced that could affect revenues and production costs. Other factors such as uncertainties regarding government regulations could also affect the results. Other risks may be set out in the Company’s annual financial statements and MD&A.

SOURCE: Stakeholder Gold Corp.

ReleaseID: 438288